Ensysce BiosciencesENSC
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 17 institutions reported holding Ensysce Biosciences Inc. (ENSC) in their 13F filings, up 6 from Q2 2025. 8 opened new positions and 2 sold out. The largest holders were Perceptive Advisors LLC ($205K), Adage Capital Partners Gp, L.L.C. ($177K) and DRW Securities, LLC ($164K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Ensysce Biosciences Inc.
- CUSIP
- 293602504
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $407K |
| Exits | 2 | $1K |
All 13F filers, Q2 2025 → Q3 2025: 174,957 shares bought and 2,411 shares sold, net +172,546 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Perceptive Advisors LLC | 0.01% | No change | 86,666 | $205K |
| Adage Capital Partners Gp, L.L.C. | 0.00% | No change | 74,711 | $177K |
| DRW Securities, LLC | 0.01% | New | 69,145 | $164K |
| Vanguard Group Inc. | 0.00% | New | 36,708 | $87K |
| Renaissance Technologies | 0.00% | New | 15,574 | $37K |
| Citadel Advisors | 0.00% | New | 14,518 | $34K |
| Virtu Financial LLC | 0.00% | New | 14,222 | $34K |
| Geode Capital Management, LLC | 0.00% | Add +28.2% | 13,030 | $31K |
| XTX Topco Ltd | 0.00% | New | 10,957 | $26K |
| Tru Independence Asset Management 2, LLC | 0.02% | New | 10,500 | $25K |
| FNY Investment Advisers, LLC | 0.00% | No change | 3,000 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -1.5% | 1,348 | $3K |
| UBS Group AG | 0.00% | Add +126.0% | 800 | $2K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -82.1% | 418 | $991 |
| BlackRock, Inc. | 0.00% | No change | 65 | $154 |
| Bank of America Corp. | 0.00% | Add +26.3% | 24 | $57 |
| Assetmark, Inc. | 0.00% | New | 13 | $31 |
"% of holder's portfolio" is ENSC's weight in each manager's 13F, not the share of Ensysce Biosciences Inc. the manager owns.